The typical profile of PD-D is characterized by a dysexecutive syndrome with prominent impairment of attention, visuospatial function, memory, and frequent behavioural symptoms. Dementia in PD has an insidious onset and slow progression, and overt symptoms are usually preceded by more subtle changes. The annual rate of decline is similar to or somewhat less than that seen in AD. Old age, longer duration of disease, and a PIGD subtype are associated with higher risk and faster progression. The severity and topography of LB-type degeneration, as well as the presence and amount of coexisting pathologies, may determine the risk of developing dementia, time to onset, and the rate of progression.


  • 1. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22: 1689-707.
  • 2. Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36-42.
  • 3. Metzler-Baddeley C. A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer’s disease and Parkinson’s disease with dementia. Cortex 2007; 43: 583-600.
  • 4. Weintraub D, Moberg PJ, Culbertson WC, et al. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol 2004; 17: 195-200.
  • 5. Aarsland D, Litvan I, Salmon D, et al. Performance on the dementia rating scale in Parkinson’s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2003; 74: 1215-20.
  • 6. Kraybill ML, Larson EB, Tsuang DW, et al. Cognitive differences in dementia patients with autopsy- verified AD, Lewy body pathology, or both. Neurology 2005; 64: 2069-73.
  • 7. Foltynie T, Brayne CEG, Robbins TW, et al. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain 2004; 127: 1-11.
  • 8. Williams-Gray CH, Foltynie T, Brayne CE, et al. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 2007; 130: 1787-98.
  • 9. Reid WG, Hely MA, Morris JG, et al. A longitudinal study of Parkinson’s disease: clinical and neuropsychological correlates of dementia. J Clin Neurosci 1996; 3: 327-33.
  • 10. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson’s disease: non-dopa responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-9.
  • 11. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-44.
  • 12. Buter TC, Van Den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease. Neurology 2008; 70: 1017-22.
  • 13. Braak H, Del Tredici K Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197-211.
  • 14. Halliday G, Hely M, Reid W, et al. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 2008; 115: 409-15.
  • 15. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006; 67: 1931-4.
  • 16. Mayeaux R, Chen J, Mirabello E, et al. An estimate of the incidence of dementia in idiopathic Parkinson’s disease. Neurology 1990; 40: 1513-17.
  • 17. Biggins CA, Boyd JL, Harrop FM et al. A controlled, longitudinal-study of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992; 55: 566-71.


  • 25
  • 18. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 2001; 56: 730-6.
  • 19. Aarsland D, Kvaloy JT, Andersen K, et al. The effect of age of onset of PD on risk of dementia. J Neurol 2007; 254: 38-45.
  • 20. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 2000; 54: 1596-602.
  • 21. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 2004; 19: 1043-9.
  • 22. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol 1992; 49: 492-7.
  • 23. Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 2002; 51: 722-9.
  • 24. Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord 2006; 21: 1123-30.
  • 25. Jacobs DM, Marder K, Cote LJ, et al. Neuropsychological characteristics of preclinical dementia in Parkinson’s disease. Neurology 1995; 45: 1691-6.
  • 26. Mahieux F, Fenelon G, Flahault A, et al. Neuropsychological prediction of dementia in Parkinson’s disease J Neurol Neurosurg Psychiatry 1998; 65: 804-5.
  • 27. Taylor JP, Rowan EN, Lett D, et al. Poor attentional function predicts cognitive decline in patients with non-demented Parkinson’s disease independent of motor phenotype. J Neurol Neurosurg Psychiatry 2008; 79: 1318-23.
  • 28. Stern Y, Marder K, Tang MX, et al. Antecedent clinical features associated with dementia in Parkinson’s disease. Neurology 1993; 43: 1690-2.
  • 29. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733-45.
  • 30. Janvin CC, Larsen JP, Aarsland D, et al. Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord 2006; 21: 1343-9.
  • 31. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013; 84: 1258-64.
  • 32. Pedersen KF, Larsen JP, Tysnes OB, et al. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. J Am Med Assoc Neurol 2013; 70: 580-6.
  • 33. Gjerstad MD, Aarsland D, Larsen JP. Development of daytime somnolence over time in Parkinson’s disease. Neurology 2002; 85: 1544-6.
  • 34. Marion MH, Qurashi M, Marshall G, et al. Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson’s disease? J Neurol 2008; 255: 192-6.
  • 35. Vendette M, Gagnon JF, Decary A et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 2007; 69: 1843-9.
  • 36. Sinforiani E, Pacchetti C, Zangaglia R, et al. REM behaviour disorder, hallucinations and cognitive impairment in Parkinson’s disease: a two-year follow up. Mov Disord 2008; 23: 1441-5.
  • 37. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-92.
  • 38. Aarsland D, Andersen K, Larsen JP. The rate of cognitive decline in Parkinson’s disease. Arch Neurol 2004; 61: 1906-11.
  • 39. Burn DJ, Rowan EN, Allan LM, et al. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy body disease. J Neurol Neurosurg Psychiatry 2006; 77: 585-9.
  • 40. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509-18.
  • 41. Aarsland D, Tandberg E, Larsen JP, et al. Frequency of dementia in Parkinson disease. Arch Neurol 1996; 53: 538-42.
  • 42. Starkstein SE, Mayberg HS, Leiguarda R, et al. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992; 55: 377-82.
  • 43. Bronnick K, Ehrt U, Emre M, et al. Attentional deficits affect activities of daily living in dementia- associated with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006; 77: 1136-42.
  • 44. Levy G, Tang MX Louis ED, et al. The association of incident dementia with mortality in PD. Neurology 2002; 59: 1708-13.
  • 45. Parkkinen L, Kauppinen T, Pirttila T, et al. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005; 57: 82-91.
  • 46. Stubendorff K, Aarsland D, Minthon L, et al. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson’s disease with dementia. PLoS ONE 2012; 7: e45451, doi: 10.1371/journal.pone.0045451.
  • 47. Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 2008; 115: 399-407.
  • 48. Colosimo C, Hughes AJ, Kilford L, et al. Lewy body cortical involvement may not always predict dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003; 74: 852-6.
  • 49. Kovari, Gold G, Herrmann FR, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol 2003; 106: 83-8.
  • 50. Compta Y, Parkkinen L, Kempster P, et al. The significance of a-synuclein, amyloid-P and tau pathologies in Parkinson’s disease progression and related dementia. Neurodegener Dis 2014; 13: 154-6.
  • 51. Beyer MK, Janvin CC, Larsen JP, et al. A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007; 78: 254-9.
  • 52. Beyer MK, Aarsland D. Grey matter atrophy in early versus late dementia in Parkinson’s disease. Parkinsonism Relat Disord 2008; 14: 620-5.
< Prev   CONTENTS   Source   Next >